Cargando…
Understanding LAG-3 Signaling
Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple biological activities over T cell activation and effector functions. LAG-3 plays a regulatory role in immunity and emerged some time ago as an inhibitory immune checkpoint molecule comparable to PD-1 and CTLA-4...
Autores principales: | Chocarro, Luisa, Blanco, Ester, Zuazo, Miren, Arasanz, Hugo, Bocanegra, Ana, Fernández-Rubio, Leticia, Morente, Pilar, Fernández-Hinojal, Gonzalo, Echaide, Miriam, Garnica, Maider, Ramos, Pablo, Vera, Ruth, Kochan, Grazyna, Escors, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156499/ https://www.ncbi.nlm.nih.gov/pubmed/34067904 http://dx.doi.org/10.3390/ijms22105282 |
Ejemplares similares
-
PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020) -
Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor
por: Chocarro, Luisa, et al.
Publicado: (2022) -
Hyperprogressive Disease: Main Features and Key Controversies
por: Arasanz, Hugo, et al.
Publicado: (2021) -
Clinical landscape of LAG-3-targeted therapy
por: Chocarro, L., et al.
Publicado: (2022) -
Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors
por: Blanco, Ester, et al.
Publicado: (2023)